AI Tool Validated for Nasogastric Tube Placement in UK Hospitals

A novel study published in the New England Journal of Medicine on February 26, 2026, demonstrates the effectiveness of a commercially available artificial intelligence (AI) tool designed to aid in nasogastric (NG) tube placement decision-making within the National Health Service (NHS) in the United Kingdom. [1] The prospective, silent trial provides external validation for the AI’s ability to support clinicians in confirming correct NG tube positioning.

The Challenge of Nasogastric Tube Placement

Nasogastric tubes are frequently used in hospitals to provide nutrition, medication, and gastric decompression. Incorrect placement of these tubes can lead to serious complications, including pneumothorax, esophageal perforation, and aspiration pneumonia. Traditionally, confirming correct placement relies on X-ray imaging, which exposes patients to radiation and can delay necessary interventions.

How the AI Tool Works

The AI tool analyzed in the study utilizes algorithms to assess NG tube placement based on various clinical parameters. The study did not detail the specific parameters used by the AI, but the results suggest it offers a non-radiological method for verifying tube position.

Study Design and Results

Researchers conducted a prospective, silent trial within the NHS. The AI tool’s recommendations were compared to the standard of care (X-ray confirmation). The study found that the AI tool demonstrated a high degree of accuracy in identifying correctly placed NG tubes. [1]

Implications for Patient Care

The validation of this AI tool has the potential to significantly improve patient care by reducing the need for X-ray confirmation of NG tube placement. This can lead to faster intervention times, reduced radiation exposure for patients, and potentially lower healthcare costs. The findings suggest that AI-assisted decision-making can play a valuable role in optimizing clinical workflows and enhancing patient safety.

Further Research and Availability

While the study provides promising results, further research is needed to assess the long-term impact of the AI tool on patient outcomes and to evaluate its performance in diverse clinical settings. The commercial availability of the AI tool was not detailed in the published study. [1]

New Findings in Cancer Treatment and HIV Therapy

The February 26, 2026 issue of the New England Journal of Medicine also featured research on advancements in cancer treatment and HIV therapy. A first-in-human trial of rezatapopt, showing selective reactivation of mutant p53 in advanced solid tumors, was published. [3] the journal highlighted new long-acting therapy options for individuals with HIV facing adherence challenges. [1]

You can browse all 2026 issues of The New England Journal of Medicine here. [2]